Channels
Conferences, News, Syndication, Xconomy »
Zillions of Biotech Conferences Want You. Which Should You Attend? |  |
|
Posted by sandiegobiotech May 20th, 2013 .
| |
| No Comments |
Biotech industry conferences are happening, somewhere on this green Earth, every day. If you’ve been around a while, and you’ve attended a few, chances are you get invitations, or marketing pitches,…
[[Click headline to continue reading.]]
Drug Development, News, Syndication, Xconomy »
San Diego’s Receptos, Ambit Biosciences, Get Ready for IPO Debuts | |
|
Posted by sandiegobiotech May 6th, 2013 .
| |
| No Comments |
[Corrected 5/6/13, 10:50 am. See below.] San Diego-based Receptos, a biotech developing new treatments for immune disorders, is among 13 IPOs expected to go public this week, according to Renaissance…
[[Click headline to continue reading.]]
More...Drug Development, News, Syndication, Xconomy »
Abide Therapeutics and Merck Unveil Diabetes Drug Collaboration | |
|
Posted by sandiegobiotech May 2nd, 2013 .
| |
| No Comments |
Abide Therapeutics, a two-year-old San Diego biopharmaceutical firm pioneering new ways to identify and validate drug targets among the serine hydrolase “superfamily” of enzymes, says today it has…
[[Click headline to continue reading.]]
Drug Discovery, News, Syndication, Xconomy »
Using Bioprinting Technology, San Diego’s Organovo Makes 3D Tissue | |
|
Posted by sandiegobiotech April 23rd, 2013 .
| |
| No Comments |
Organovo, a San Diego regenerative medicine company developing bio-printing technology, says it has used its proprietary NovaGen bioprinter to produce 3D samples of human liver cells that show some…
[[Click headline to continue reading.]]
More...Diagnostics, News, Syndication, Xconomy »
Thermo Fisher Scientific Acquires Life Technologies in $13.6B Deal | |
|
Posted by sandiegobiotech April 15th, 2013 .
| |
| No Comments |
Waltham, MA-based Thermo Fisher Scientific (NYSE: TMO) said today it will pay $13.6 billion to acquire Carlsbad, CA-based Life Technologies (NASDAQ: LIFE) following an auction that began in January…
[[Click headline to continue reading.]]
More...Drug Development, News, Syndication, Xconomy »
Rare FDA Ruling Triggers Stampede for Acadia Pharmaceuticals | |
|
Posted by sandiegobiotech April 11th, 2013 .
| |
| No Comments |
How often does the FDA tell a drug developer to dispense with a requisite, second late-stage trial—and to proceed with filing a new drug application? Shares of San Diego’s Acadia…
[[Click headline to continue reading.]]
Drug Development, News, Syndication, Xconomy »
Rare FDA Ruling Triggers Stampede for Acadia Pharmaceuticals | |
|
Posted by sandiegobiotech April 11th, 2013 .
| |
| No Comments |
How often does the FDA tell a drug developer to dispense with a requisite, second late-stage trial—and to proceed with filing a new drug application? Shares of San Diego’s Acadia…
[[Click headline to continue reading.]]
Drug Development, News, Syndication, Xconomy »
Rare FDA Ruling Triggers Stampede for Acadia Pharmaceuticals | |
|
Posted by sandiegobiotech April 11th, 2013 .
| |
| No Comments |
How often does the FDA tell a drug developer to dispense with a requisite, second late-stage trial—and to proceed with filing a new drug application? Shares of San Diego’s Acadia…
[[Click headline to continue reading.]]
Drug Development, News, Syndication, Xconomy »
Rare FDA Ruling Triggers Stampede for Acadia Pharmaceuticals | |
|
Posted by sandiegobiotech April 11th, 2013 .
| |
| No Comments |
How often does the FDA tell a drug developer to dispense with a requisite, second late-stage trial—and to proceed with filing a new drug application? Shares of San Diego’s Acadia…
[[Click headline to continue reading.]]
Drug Development, News, Syndication, Xconomy »
San Diego’s Ambrx Working with Astellas to Develop Anti-Cancer Drugs | |
|
Posted by sandiegobiotech April 8th, 2013 .
| |
| No Comments |
San Diego-based Ambrx says it’s getting an upfront payment of $15 million under a deal with Japan’s Astellas to help develop an undisclosed number of targets for antibody drug conjugates in cancer….
[[Click headline to continue reading.]]
